Tilmanocept
"Conduced first exploratory use in June, 2013 indication cutaneous melanoma, Breslow/3mm.  Tilmanocept was well received by the patient with no local. Clearance delay provision <20 min. SLN discovery total <4 min/2 SLN/Path."